Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Zydus Cadila's three-dose Covid vaccine ZyCoV-D is set to be included in the national anti-coronavirus inoculation programme this month with the Centre placing&nbsp;a&nbsp;purchase&nbsp;order&nbsp;with the Ahmedabad-based firm for one crore doses, official sources told news agency PTI.
The Union Health Ministry is learnt to have given the go ahead to initiate the preparatory work for the introduction of the indigenously developed world's first DNA-based&nbsp;Covid jab, which in all probability will be given to adults initially under the country's vaccination drive, sources in the know of developments said.Read/Watch Also: Everything you need to know about Zycov-D
ZyCoV-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above.
"The Centre has already placed a&nbsp;purchase&nbsp;order&nbsp;with Zydus&nbsp;Cadila for supply of one crore doses of ZyCoV-D, each costing&nbsp;around Rs 358 excluding&nbsp;taxes,&nbsp;at the earliest. This price includes the cost of a&nbsp;disposable painless jet applicator&nbsp;which has to be used for administering each dose," an official source said.
"The vaccine in all probability will be given to adults initially because of limited production capacity," the source said.
Zydus Cadila&nbsp;is in a position to provide one crore doses of ZyCoV-D per month, company officials are learnt to have conveyed to the ministry.
For administering to adults, frontline workers and vaccinators will be provided a brief training for using the needle-free pharma jet application in actual field settings.
The three doses of ZyCoV-D are to be administered 28 days apart, with each dose comprising a shot in both arms.
ZyCoV-D received emergency use authorisation from the drug regulator on August 20.
Meanwhile, a comprehensive programme for paediatric immunisation including developing a priority list of comorbidities is being worked out by the NTAGI (National Technical Advisory Group on Immunisation)&nbsp;for the launch of ZyCoV-D and Covaxin.&nbsp;&nbsp; As for the emergency use approval for Bharat Biotech's Covaxin in the 2 to 18 years age group by the Drugs Controller General of India, it is under expert opinion and evaluation, official sources said.
The Subject Expert Committee (SEC) on COVID-19 of the Central Drug Authority on October 12&nbsp; had recommended granting emergency use authorisation to Covaxin for children and adolescents in the 2 to 18 years age group with certain conditions.
At present, every citizen who is 18 years or above is eligible for the vaccination drive

Govt places order for one crore doses of Zydus Cadila's needle-free Covid vaccine 

Cadila Health's DNA-based , needle free vaccine Zycov-D to be available soon as Govt places order for 1 crore doses. 

Zycov-D needle free vaccine to debut this month

Zydus Cadila's three-dose Covid vaccine ZyCoV-D is set to be included in the national anti-coronavirus inoculation programme this month with the Centre placing&nbsp;a&nbsp;purchase&nbsp;order&nbsp;with the Ahmedabad-based firm for one crore doses, official sources told news agency PTI.
ZyCoV-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above. "The Centre has already placed a&nbsp;purchase&nbsp;order&nbsp;with Zydus&nbsp;Cadila for supply of one crore doses of ZyCoV-D, each costing&nbsp;around Rs 358 excluding&nbsp;taxes,&nbsp;at the earliest. This price includes the cost of a&nbsp;disposable painless jet applicator&nbsp;which has to be used for administering each dose," an official source said.
The three doses of ZyCoV-D are to be administered 28 days apart, with each dose comprising a shot in both arms.
ZyCoV-D received emergency use authorisation from the drug regulator on August 20.

ZyCoV-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above.&nbsp;

Zydus Cadila's three-dose Covid vaccine ZyCoV-D is set to be included in the national anti-coronavirus inoculation programme this month with the Centre placing&nbsp;a&nbsp;purchase&nbsp;order&nbsp;with the Ahmedabad-based firm for one crore doses, official sources told news agency PTI.
The Union Health Ministry is learnt to have given the go ahead to initiate the preparatory work for the introduction of the indigenously developed world's first DNA-based&nbsp;Covid jab, which in all probability will be given to adults initially under the country's vaccination drive, sources in the know of developments said. Read/Watch Also: <a href="https://www.editorji.com/story/meet-zycov-d-the-world-s-first-dna-covid-19-vaccine-everything-you-need-to-know-about-the-new-vaccine-1629658709134">Everything you need to know about Zycov-D</a>
ZyCoV-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above.
"The Centre has already placed a&nbsp;purchase&nbsp;order&nbsp;with Zydus&nbsp;Cadila for supply of one crore doses of ZyCoV-D, each costing&nbsp;around Rs 358 excluding&nbsp;taxes,&nbsp;at the earliest. This price includes the cost of a&nbsp;disposable painless jet applicator&nbsp;which has to be used for administering each dose," an official source said.
"The vaccine in all probability will be given to adults initially because of limited production capacity," the source said.
Zydus Cadila&nbsp;is in a position to provide one crore doses of ZyCoV-D per month, company officials are learnt to have conveyed to the ministry.
For administering to adults, frontline workers and vaccinators will be provided a brief training for using the needle-free pharma jet application in actual field settings.
The three doses of ZyCoV-D are to be administered 28 days apart, with each dose comprising a shot in both arms.
ZyCoV-D received emergency use authorisation from the drug regulator on August 20.
Meanwhile, a comprehensive programme for paediatric immunisation including developing a priority list of comorbidities is being worked out by the NTAGI (National Technical Advisory Group on Immunisation)&nbsp;for the launch of ZyCoV-D and Covaxin.&nbsp;&nbsp; As for the emergency use approval for Bharat Biotech's Covaxin in the 2 to 18 years age group by the Drugs Controller General of India, it is under expert opinion and evaluation, official sources said.
The Subject Expert Committee (SEC) on COVID-19 of the Central Drug Authority on October 12&nbsp; had recommended granting emergency use authorisation to Covaxin for children and adolescents in the 2 to 18 years age group with certain conditions.
At present, every citizen who is 18 years or above is eligible for the vaccination drive

Cadila Healthcare&nbsp;is buzzing in trade as&nbsp;Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world's first Plasmid DNA vaccine for Covid-19. Brokergaes&nbsp;from Morgan Stanley to CLSA&nbsp;are extremely bullish on the stock on the prospect of the vaccine&nbsp;CLSA&nbsp;on Cadila&nbsp;Health: Upgraded the stock to a buy with target of Rs 650/share which is a 20% upside from Friday's close. The brokerage expects a double digit growth from the core business and says the recent correction now offers a good entry point.&nbsp;Morgan Stanley on Cadila&nbsp;Health: Though Morgan is keeping an equal weight they have a more aggressive price target at Rs 664/share as they expect the vaccine launch will provide the pivot to the stock and expect large scale&nbsp;adoption of the dose.&nbsp;

Cadila gets the right dose! Brokerages bullish after Covid 19 vaccine nod, upgrades from CLSA & Morgan 

Cadila gets the right dose! Brokerages bullish after Covid 19 vaccine nod, upgrades from CLSA, Morgan Stanley.&nbsp;

The Zycov D bullish bet

Company expects to launch the vaccine in September, pricing not yet decided.&nbsp;

Cadila Healthcare&nbsp;is buzzing in trade as&nbsp;Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world's first Plasmid DNA vaccine for Covid-19. Brokergaes&nbsp;from Morgan Stanley to CLSA&nbsp;are extremely bullish on the stock on the prospect of the vaccine&nbsp; CLSA&nbsp;on Cadila&nbsp;Health: Upgraded the stock to a buy with target of Rs 650/share which is a 20% upside from Friday's close. The brokerage expects a double digit growth from the core business and says the recent correction now offers a good entry point.&nbsp; Morgan Stanley on Cadila&nbsp;Health: Though Morgan is keeping an equal weight they have a more aggressive price target at Rs 664/share as they expect the vaccine launch will provide the pivot to the stock and expect large scale&nbsp;adoption of the dose.&nbsp;

In what would be a game changer for the vaccine drive against Covid&nbsp;19,&nbsp;Cadila Health has applied to DCGI for emergency use authorisation to launch ZyCoV-D vaccine for for COVID-19. Here is why is this vaccine significant-:&nbsp;

Cadila Health says ZyCoV-D effective against #Delta variant and other mutant strains of Covid-19
Cadila&nbsp;also claims&nbsp;ZyCoV-D safe for children in the age group of 12-18 years as per studies
Vaccine could be available as early as August&nbsp;
Cadila&nbsp;plans to manufacture 10 crore&nbsp;doses annually

ZyCoV-D is a plasma DNA based vaccine for Covid 19 studies and&nbsp;Cadila Health has&nbsp;conducted over 50 clinical sites across India

Vaccine Alert: Cadila applies for nod for ZyCoV-D; says vaccine safe for children between 12-18

In a game changer Cadila&nbsp;applies for approval for "children safe" Covid vaccine&nbsp;ZyCoV-D.&nbsp;

ZyCoV-D vaccine safe for children: Cadila Health 

vaccine, children, Cadila Health, ZyCoV-D

ZyCoV-D is world's first&nbsp;first DNA-based vaccine, Cadila&nbsp;Health ready to supply safe for children vaccine as early as August.&nbsp;

In what would be a game changer for the vaccine drive against Covid&nbsp;19,&nbsp;Cadila Health has applied to DCGI for emergency use authorisation to launch ZyCoV-D vaccine for for COVID-19. Here is why is this vaccine is significant-:&nbsp;
<ul>
<li>Cadila Health says ZyCoV-D effective against #Delta variant and other mutant strains of Covid-19</li>
<li>Cadila&nbsp;also claims&nbsp;ZyCoV-D safe for children in the age group of 12-18 years as per studies.&nbsp;</li>
<li>Vaccine could be available as early as August in the market pending approvals</li>
<li>Cadila&nbsp;plans to manufacture 10 crore&nbsp;doses annually</li>
</ul>
ZyCoV-D is a plasma DNA based vaccine for Covid 19 studies and&nbsp;Cadila Health has&nbsp;conducted trials over 50 clinical sites across India.&nbsp;
Also See |<a href="https://www.editorji.com/story/serum-denied-permission-for-covid-vaccine-covovax-trials-on-children-1625109901643" target="_blank"> Serum denied nod for Covovax&nbsp;trials on children</a>

cadila health

Categories